Clinical trials: Inflammation; Skin
Atopic Dermatitis (AD)
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis
- Trial name
- NCT05372653
- Testing
- OPA-15406
- Where
- Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid…
- Trial name
- PREDICTRA (NCT02198651)
- Testing
- Adalimumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 149 people
- Sponsor
- AbbVie
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of…
- Trial name
- NCT03539601
- Testing
- Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%
- Where
- 32 sites in United States, Germany and 5 more
- Volunteers
- 237 people
- Sponsor
- Pfizer
Atopic Dermatitis
VANOS Cream and Skin Barrier Function
The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis.
- Trial name
- NCT00819507
- Testing
- Fluocinonide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Dandruff, Seborrheic Dermatitis
Cleansing Device for the Treatment of Scalp and Hair Conditions
The objective of this study is to evaluate an improvement of scalp health after the use of an investigational off-label WaterPik and brush device aimed to massage and cleanse the scalp.
- Conditions
- Dandruff, Seborrheic Dermatitis, Hair Loss
- Trial name
- NCT05319444
- Testing
- Off-brand Waterpik®
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Rheumatoid Arthritis, Psoriatic Arthritis
Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis
This laboratory study will investigate the impact of cannabis on pain, affect, and inflammation among patients with rheumatoid or psoriatic arthritis (n = 76).
- Trial name
- NCT04269993
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Brown University
Breast Cancer, Radiation Dermatitis
MediHoney for Radiation Dermatitis
The aim of this study is to compare the effects of Medihoney and Hydrophor on radiation dermatitis reactions in a group of women undergoing radiation therapy for breast cancer.
- Trial name
- NCT02234479
- Testing
- Hydrophor (Group A), MediHoney (Group B)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Breast Carcinoma
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
This trial studies how well a lifestyle intervention works in reducing breast cancer risk through changing body composition and decreasing inflammation in normal weight women.
- Trial name
- NCT04267796
- Testing
- Aerobic Exercise, Dietary Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Abscess, Wound Infection
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the…
- Conditions
- Abscess, Wound Infection, Diabetic Foot, Ulcer
- Trial name
- NCT00402727
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- Where
- 123 sites in Austria, Belgium and 18 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- SCULPTURE (NCT01406938)
- Testing
- AIN457 150mg, AIN457 300mg
- Where
- 131 sites in United States, Austria and 14 more
- Volunteers
- 967 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Carcinoma, Radiation-Induced Dermatitis
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation…
- Trial name
- NCT02369835
- Testing
- Dakin's solution
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Stanford University
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Prurigo Nodularis
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
- Trial name
- NCT04501679
- Testing
- Nemolizumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 274 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Mepolizumab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that acts on Interleukin-5 (IL-5), which is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils…
- Trial name
- NCT03055195
- Testing
- Mepolizumab 100 mg
- Where
- 20 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT03607422
- Testing
- Upadacitinib
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
- Trial name
- BREEZE-AD3 (NCT03334435)
- Testing
- Baricitinib
- Where
- 185 sites in Argentina, Australia and 17 more
- Volunteers
- 1,645 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic dermatitis (AD) is a chronic disease associated with intense itching, which affects most aspects of everyday life in the majority of patients.
- Trial name
- NCT01806662
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Rockefeller University